Regeneron Pharmaceuticals Inc Oncology Investor Event ASH 2020 Transcript
Hello. Thank you for holding, and welcome to the Regeneron Oncology Investor Event ASH 2020. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions)
I would like to turn the call to the Head of Investor Relations, Mr. Justin Holko. Please go ahead.
Welcome, everyone, to Regeneron's Oncology Hematology ASH 2020 webcast. Joining me on the call today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Dr. David Weinreich, Senior Vice President and Head of Commercial and Clinical Development; Dr. Andres Sirulnik, Senior Vice President, Translational and Clinical Sciences Hematology; and Dr. Israel Lowy, Senior Vice President of Translational Sciences and Oncology.
After our prepared remarks, we will open the call for Q&A.
Before handing the call over to George, I would like to remind you that remarks made on today's call include forward-looking statements about Regeneron, including those relating to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |